605 related articles for article (PubMed ID: 36528470)
1. Single-Agent Neoadjuvant Immunotherapy With a PD-1 Antibody in Locally Advanced Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer.
Pei F; Wu J; Zhao Y; He W; Yao Q; Huang M; Huang J
Clin Colorectal Cancer; 2023 Mar; 22(1):85-91. PubMed ID: 36528470
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Neoadjuvant Monoimmunotherapy With PD-1 Inhibitor for dMMR/MSI⁃H Locally Advanced Colorectal Cancer: A Single-Center Real-World Study.
Zhang X; Yang R; Wu T; Cai X; Li G; Yu K; Li Y; Ding R; Dong C; Li J; Hu R; Feng Q; Li Y
Front Immunol; 2022; 13():913483. PubMed ID: 35958603
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant Immunotherapy With Ipilimumab Plus Nivolumab in Mismatch Repair Deficient/Microsatellite Instability-High Colorectal Cancer: A Preliminary Report of Case Series.
Pan T; Yang H; Wang WY; Rui YY; Deng ZJ; Chen YC; Liu C; Hu H
Clin Colorectal Cancer; 2024 Mar; 23(1):104-110. PubMed ID: 38336555
[TBL] [Abstract][Full Text] [Related]
4. Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer.
Trojan J; Stintzing S; Haase O; Koch C; Ziegler P; Demes M; Jelas I
Oncologist; 2021 Dec; 26(12):e2110-e2114. PubMed ID: 34431576
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial.
Hu H; Kang L; Zhang J; Wu Z; Wang H; Huang M; Lan P; Wu X; Wang C; Cao W; Hu J; Huang Y; Huang L; Wang H; Shi L; Cai Y; Shen C; Ling J; Xie X; Cai Y; He X; Dou R; Zhou J; Ma T; Zhang X; Luo S; Deng W; Ling L; Liu H; Deng Y
Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):38-48. PubMed ID: 34688374
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities.
Zhang X; Wu T; Cai X; Dong J; Xia C; Zhou Y; Ding R; Yang R; Tan J; Zhang L; Zhang Y; Wang Y; Dong C; Li Y
Front Immunol; 2022; 13():795972. PubMed ID: 35371084
[TBL] [Abstract][Full Text] [Related]
7. Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair.
Ratovomanana T; Cohen R; Svrcek M; Renaud F; Cervera P; Siret A; Letourneur Q; Buhard O; Bourgoin P; Guillerm E; Dorard C; Nicolle R; Ayadi M; Touat M; Bielle F; Sanson M; Le Rouzic P; Buisine MP; Piessen G; Collura A; Fléjou JF; de Reyniès A; Coulet F; Ghiringhelli F; André T; Jonchère V; Duval A
Gastroenterology; 2021 Sep; 161(3):814-826.e7. PubMed ID: 33992635
[TBL] [Abstract][Full Text] [Related]
8. [Multicenter real-world study on safety and efficacy of neoadjuvant therapy in combination with immunotherapy for colorectal cancer].
Liu XZ; Xiong Z; Xiao BY; Yu GY; Li YJ; Yao YF; Tao KX; Ding PR; Zhang W; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Mar; 25(3):219-227. PubMed ID: 35340171
[No Abstract] [Full Text] [Related]
9. A Phase II Study of Avelumab Monotherapy in Patients with Mismatch Repair-Deficient/Microsatellite Instability-High or POLE-Mutated Metastatic or Unresectable Colorectal Cancer.
Kim JH; Kim SY; Baek JY; Cha YJ; Ahn JB; Kim HS; Lee KW; Kim JW; Kim TY; Chang WJ; Park JO; Kim J; Kim JE; Hong YS; Kim YH; Kim TW
Cancer Res Treat; 2020 Oct; 52(4):1135-1144. PubMed ID: 32340084
[TBL] [Abstract][Full Text] [Related]
10. Complete pathological response after chemotherapy or immune checkpoint inhibitors in deficient MMR metastatic colorectal cancer: Results of a retrospective multicenter study.
Marolleau P; Tougeron D; Allignet B; Cohen R; Sefrioui D; Gallet B; Dumont F; Guimbaud R; Alouani E; Passot G; Desolneux G; Ghiringhelli F; Marchal F; Mourthadhoi F; Coriat R; Desgrippes R; Locher C; Goujon G; Des Guetz G; Aparicio T; Paubelle E; Dupré A; de la Fouchardière C
Int J Cancer; 2023 Oct; 153(7):1376-1385. PubMed ID: 37403609
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis of neoadjuvant immunotherapy for non-metastatic colorectal cancer.
Zhou L; Yang XQ; Zhao GY; Wang FJ; Liu X
Front Immunol; 2023; 14():1044353. PubMed ID: 36776899
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant Immunotherapy Leads to Major Response and Low Recurrence in Localized Mismatch Repair-Deficient Colorectal Cancer.
Xiao BY; Zhang X; Cao TY; Li DD; Jiang W; Kong LH; Tang JH; Han K; Zhang CZ; Mei WJ; Xiao J; Pan ZZ; Li YF; Zhang XS; Ding PR
J Natl Compr Canc Netw; 2023 Jan; 21(1):60-66.e5. PubMed ID: 36630898
[TBL] [Abstract][Full Text] [Related]
13. PD-1 blockade in neoadjuvant setting of DNA mismatch repair-deficient/microsatellite instability-high colorectal cancer.
Liu DX; Li DD; He W; Ke CF; Jiang W; Tang JH; Kong LH; Li Y; Sui QQ; Xiao BY; Li WR; Hong ZG; Xu RH; Pan ZZ; Zhang XS; Ding PR
Oncoimmunology; 2020; 9(1):1711650. PubMed ID: 32042474
[No Abstract] [Full Text] [Related]
14. Neoadjuvant treatment of sintilimab plus hypofractionated radiotherapy for MSI-H/dMMR rectal cancer: A prospective, multicenter, phase Ib study.
Li X; Fang C; Wang X; Yu Y; Wang Z; Qiu M
Cancer Med; 2022 Dec; 11(23):4405-4410. PubMed ID: 35352512
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of neoadjuvant immunotherapy in patients with microsatellite instability-high gastrointestinal malignancies: A case series.
Zhang Z; Cheng S; Gong J; Lu M; Zhou J; Zhang X; Li J; Shen L; Peng Z
Eur J Surg Oncol; 2020 Oct; 46(10 Pt B):e33-e39. PubMed ID: 32732092
[TBL] [Abstract][Full Text] [Related]
16. Locally advanced rectal cancer with dMMR/MSI-H may be excused from surgery after neoadjuvant anti-PD-1 monotherapy: a multiple-center, cohort study.
Yang R; Wu T; Yu J; Cai X; Li G; Li X; Huang W; Zhang Y; Wang Y; Yang X; Ren Y; Hu R; Feng Q; Ding P; Zhang X; Li Y
Front Immunol; 2023; 14():1182299. PubMed ID: 37441082
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant immunotherapy for dMMR/MSI-H locally advanced rectal cancer: The future new standard approach?
Cabezón-Gutiérrez L; Custodio-Cabello S; Palka-Kotlowska M; Díaz-Pérez D; Mateos-Dominguez M; Galindo-Jara P
Eur J Surg Oncol; 2023 Feb; 49(2):323-328. PubMed ID: 36400657
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneity of Mismatch Repair Status and Microsatellite Instability between Primary Tumour and Metastasis and Its Implications for Immunotherapy in Colorectal Cancers.
Evrard C; Messina S; Sefrioui D; Frouin É; Auriault ML; Chautard R; Zaanan A; Jaffrelot M; De La Fouchardière C; Aparicio T; Coriat R; Godet J; Silvain C; Randrian V; Sabourin JC; Guimbaud R; Miquelestorena-Standley E; Lecomte T; Moulin V; Karayan-Tapon L; Tachon G; Tougeron D
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457245
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological characteristics of high microsatellite instability/mismatch repair-deficient colorectal cancer: A narrative review.
Mei WJ; Mi M; Qian J; Xiao N; Yuan Y; Ding PR
Front Immunol; 2022; 13():1019582. PubMed ID: 36618386
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study.
Chen G; Jin Y; Guan WL; Zhang RX; Xiao WW; Cai PQ; Liu M; Lin JZ; Wang FL; Li C; Quan TT; Xi SY; Zhang HZ; Pan ZZ; Wang F; Xu RH
Lancet Gastroenterol Hepatol; 2023 May; 8(5):422-431. PubMed ID: 36870360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
